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Background: Dogs with hypoadrenocorticism (HA) frequently show signs of gastroin-
testinal disease (SGD). The prevalence of dogs presented for chronic SGD with HA is
unknown.
Objectives: The aims of this study were to determine the prevalence of HA in dogs
with chronic SGD and to identify clinical and laboratory variables for HA in this
population.
Animals: One hundred fifty-one dogs with chronic SGD.
Methods: In this multicentered prevalence study a standardized workup was per-
formed in prospectively enrolled dogs with SGD > 3 weeks duration. Basal serum cor-
tisol concentration was measured in every dog with ACTH stimulation test (ACTHST)
if basal serum cortisol concentration was <3 μg/dL.
Results: Basal serum cortisol concentration was <3 μg/dL in 80/151 (53%) dogs,
<2 μg/dL in 42/151 (28%) dogs, and < 1 μg/dL in 9/151 (6%) dogs. In 6/151 dogs HA
was diagnosed based on ACTHST (stimulated serum cortisol concentration < 2 μg/
dL), a prevalence of 4%. There was no difference in history, physical examination, and
laboratory variables between dogs with HA and those with other causes of chronic
Abbreviations: ACTHST, ACTH stimulation test; ALT, alanine aminotransferase; CI, confidence interval; GDH, glucocorticoid-deficient hypoadrenocorticism; GI, gastrointestinal; GIS,
gastrointestinal signs; GSAVA, German Small Animal Veterinary Association; HA, hypoadrenocorticism; HPA, hypothalamus-pituitary-adrenal axis; MGDH, mineralocorticoid- and glucocorticoid
deficient hypoadrenocorticism; SGD, signs of gastrointestinal disease.
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SGD. In 4/6 dogs with HA, there was melena or hematochezia indicating gastrointes-
tinal blood loss. Hyperkalemia, hyponatremia, or both was not observed in any dog.
Conclusion and Clinical Importance: The prevalence of HA among dogs with chronic
SGD is higher than in the general population. Based on these results, testing adrenal
function should be performed as a standard screening test in dogs with chronic SGD
to differentiate between HA and chronic enteropathies.
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1 | INTRODUCTION
Hypoadrenocorticism (HA) is an uncommon endocrinopathy in dogs
with prevalence ranges from 0.06 to 0.28% with 0.09% of an insured
dog population in Sweden being affected.1,2 There is an increased risk
for HA in Portuguese Water Dogs, Standard Poodles, Bearded Collies,
Cairn Terrier, and Cocker Spaniels.2 There is also a genetic predisposi-
tion for HA in breeds such as the Nova Scotia Duck Tolling Retriever,
Leonberger and Pomeranian, with the highest prevalence (9.73%) in
Great Pyrenees dogs.3,4
It is assumed that primary HA results from a slowly progressing
immune-mediated destruction and consecutive atrophy of the adrenal
cortex, which is also the most common cause for Addison's disease in
humans.5-7 Rare other causes include trauma and infiltrative damage
by neoplasia, abscess, and granulomatous inflammation.8-10
In most cases of HA gradual destruction of all 3 layers of the
adrenal cortex results in an inadequate secretion of both mineralocor-
ticoid and glucocorticoid hormones (MGDH), leading to typical elec-
trolyte imbalances (namely hyperkalemia, hyponatremia, and often
also hypochloremia) with sometimes dramatic clinical conse-
quences.11,12 However, up to 30% of dogs with HA have what has
been termed atypical or glucocorticoid deficient HA (GDH) where
electrolyte concentrations remain within the reference range.11 The
absence of typical laboratory abnormalities makes GDH more difficult
to diagnose in a clinical setting.
Dogs with HA are frequently presented with vague, episodic, and
nonspecific clinical signs including anorexia (89%), vomiting (72%),
weight loss (42%), and diarrhea (35%).11,13
Signs of gastrointestinal disease (SGD) secondary to a lack of glu-
cocorticoids are indistinguishable from clinical signs caused by primary
GI disorders.11,14-16 In the absence of electrolyte abnormalities, subtle
laboratory abnormalities might lead to a suspicion of HA. These can
include the lack of a stress leukogram, relative or absolute lymphocy-
tosis, eosinophilia, prerenal azotemia, hypoalbuminemia, hypoglycemia
or hypercalcemia.11,13,17 However, these changes are nonspecific,
have a number of possible causes and do not help to discriminate pri-
mary GI disease from HA.
Hence, diagnosis of HA, especially GDH, is dependent on adrenal
gland function testing, such as ACTH-stimulation test
(ACTHST).11,12,17 This multicenter study was conducted in order to
evaluate the necessity of performing this relatively expensive and
time-consuming test in dogs with chronic SGD. The primary aim was
to assess the prevalence of HA in dogs with chronic SGD. The sec-
ondary aim was to identify clinical and laboratory variables that might
help to identify or exclude HA in this group of dogs before performing
ACTHST, especially in comparison to other dogs with chronic SGD
that do not have HA.
2 | MATERIALS AND METHODS
2.1 | Study design and general diagnostic workup
This study was conducted prospectively by members of the German
Small Animal Veterinary Association (GSAVA) Working Group for Gas-
troenterology at 6 different private or university referral hospitals.
Ethical approval was obtained according to German animal welfare
laws (approval no.: 37-24-11-2014). Each owner was informed about
the purpose of the study and signed a consent form stating that blood
samples were used for scientific research projects.
Between November 2014 and December 2015, dogs older than
6 months of age presenting with chronic (>3 weeks) SGD such as
vomiting, regurgitation, diarrhea, weight loss, or anorexia were offered
enrolment. Dogs treated with steroids were only included if (1) short-
acting corticosteroids (<12 hours; eg, hydrocortisone) were given for
not more than 1 week and had been discontinued for at least 1 week
before enrolment; (2) intermediate-acting corticosteroids (12-36 hours;
eg, prednisolone) were given for not more than 1 week and had been
discontinued for at least 4 weeks before enrolment; and (3) long-acting
corticosteroids (>36 hours; eg, dexamethasone) had been discontinued
for at least 3 months before enrolment. These criteria were selected on
the basis of a consensus between 3 endocrinologists and the authors.
There are no published guidelines about the delay required for ade-
quate adrenal function recovery after administration of different corti-
costeroids, and the best timing for performing an ACTH stimulation.
Clinical signs were quantified using the canine chronic enteropa-
thy clinical activity index (CCECAI).18 Diagnostic workup consisted of
a complete blood count, routine biochemistry profile including elec-
trolytes, and determination of serum TLI, cPL, folate and cobalamin
concentration in all dogs.
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Clinicians were given the choice to send blood count and bio-
chemistry to 1 of 2 laboratories (IDEXX Laboratories, Ludwigsburg,
Germany and Central Laboratory Animal Research Facility, University
Utrecht). At Idexx Laboratories blood count was measured using
Sysmex XT and biochemistry was measured using Beckman
AU5800.19
In Utrecht blood count was measured using Siemens ADVIA
2120 and biochemistry was measured using Hitachi 912 (Roche Diag-
nostics GmbH, Germany).
Fecal parasitology (flotation, standard egg count) was performed
in every dog if recent fecal testing results from the referring veteri-
nary surgeon were not available. Further diagnostic workup including
diagnostic imaging modalities was performed based on individual clini-
cian's decisions and availability.
2.2 | Endocrine testing and cortisol measurements
Basal serum cortisol concentration was determined in all dogs. An
ACTHST was performed if basal serum cortisol concentration was
<3 μg/dL (<83 nmol/L) or without waiting for the result of the basal
cortisol dictated by the dog's clinical signs or the owner's willingness
to return for the test. A basal cortisol level of 3 μg/dL as cutoff for
adrenal testing was empirically chosen to ensure not to miss any dog
with hypoadrenocorticism.20,21
For the ACTHST 5 μg/kg synthetic ACTH (Synacthen, Alfasigma
S.p.A., Milan, Italy) was administered by intravenous injection and
serum cortisol concentration determined before and 1 hour after
ACTH administration.22 The diagnosis of HA was defined by a stimu-
lated serum cortisol concentration ≤2 μg/dL.23
Cortisol concentration was measured using a solid phase, compet-
itive chemiluminescent enzyme immunoassay (IMMULITE 2000 Corti-
sol, Siemens) validated for dogs.24,25
Clinicians were given the choice to send samples for cortisol
determination to 1 of 2 laboratories (IDEXX Laboratories, Ludwigs-
burg, Germany and Central Laboratory Animal Research Facility, Uni-
versity Utrecht), both using the same methodology.
2.3 | Statistical evaluation and presentation of
the data
A sample size analysis was performed using G*Power 3. and BIAS for
Windows 11.01 g software.26 For evaluation of the HA prevalence a
maximum prevalence of 5% was postulated and the maximum range
of the 95% confidence interval was defined as 7%. For evaluation of
the laboratory findings an effective size Cohen's d > 1, a P-value <.05
and a minimum power of 80% was predetermined.
Statistical analyses were conducted with IBM SPSS 23.0 (IBM
Germany GmbH, Ehningen, Germany), MedCalc Statistical Software
version 17.9.7 (MedCalc Software bvba, Ostend, Belgium), and BIAS
for Windows 11.01(Epsilon Ed., Frankfurt, Germany). Normal distribu-
tion of data was determined by Kolmogorov-Smirnoff test. Data were
compared using Fisher's exact and Mann-Whitney U test. Statistical
significance was defined as P < .05.
The prevalence and its 95% confidence interval (CI) according to
Wilson were calculated. A binomial test was used to compare the
prevalence of HA with the 2 reported values of 0.06 and 0.28%.1
3 | RESULTS
Of 151 dogs (41 dogs from the Clinic of Small Animal Medicine LMU
Munich Germany, 70 dogs from Small Animal Hospital Internal Medi-
cine, Justus Liebig University Gießen, Germany and 40 dogs from
Division of Small Animal Internal Medicine, Department of Clinical
Sciences of Companion Animals, Faculty of Veterinary Medicine,
Utrecht University, Netherlands) enrolled in the study, 6 dogs were
diagnosed with HA (all of them GDH). The calculated prevalence was
4.0% (95% CI: 1.8%-8.4%). A binomial test indicated that the propor-
tion of dogs with SGD was significantly higher (P < .001) than the
expected prevalence of 0.06 or 0.28% (1-sided).1,2
3.1 | Signalment and history
3.1.1 | Dogs without HA (n = 145)
Most common breeds of dogs without HA were mixed breed dogs
(n = 35), Golden Retriever (n = 8), Labrador Retriever (n = 7), Poodle
(n = 7), Dachshund (n = 7), German Shepherd (n = 6), Jack Russel Ter-
rier (n = 5), Yorkshire Terrier (n = 5), French Bulldog (n = 5), Collie
(n = 3), Hovawart (n = 3), Rottweiler (n = 3) and 51 other purebred
dogs of 42 different breeds. Eighty-two dogs were male, of which
41 were neutered, and 63 female, of which 34 were spayed. Median
age was 4.0 years (range: 1 year to 15 years) and median body weight
was 17.7 kg (range: 1.8-71.7 kg).
Median duration of SGD was 5 months (range: 1-96 months).
Most frequent presenting complaints were abnormal fecal or stool
consistency (106/141; 75%), increased defecation frequency (85/135;
63%), mucoid feces (49/140; 35%), tenesmus (32/140; 23%), hem-
atochezia (35/140; 32%), and melena (9/141; 6%). Fifty-two percent
of dogs had a history of chronic vomiting (17% 1x/week; 12% 2-3x/
week; 23% >3x/week). Median CCECAI was 5 (range: 1-20), which
reflects mild disease activity.
3.1.2 | Dogs with HA (n = 6)
Dogs with HA consisted of 3 mixed breed dogs, and 1 each of the fol-
lowing breeds: Standard Poodle, Basset hound, and German Shepherd
dog. Three dogs were male, of which 1 was neutered, and 3 were
spayed females. Median age was 5 years (range: 3-11 years) and
median body weight was 23.9 kg (range: 8.5-31.0 kg). Median dura-
tion of SGD until presentation was 3 months (range: 1-36 months).
Signs of gastrointestinal disease were abnormal fecal or stool
HAUCK ET AL. 1401
consistency (5/6), increased defecation frequency (5/6), mucoid feces
(3/5), melena (2/6), hematochezia (4/6), and tenesmus (1/5). Four
dogs had a history of chronic vomiting (1 dog 1x/week; 3 dogs 2-3x/
week). The median CCECAI in the 6 dogs with HA was 6.5 (range:
3-10), reflecting a moderate disease activity.
No statistical difference concerning breed (P = .12), age (P = .31),
sex (P = .75), body weight (P = .68), and severity of clinical signs
(P = .67) between dogs with and without HA was detected.
3.2 | Laboratory findings
Laboratory variables of dogs with and without HA are shown in
Tables 1–3. There was no significant difference in any laboratory vari-
able between groups. In dogs without HA 6 dogs had hyponatremia,
2 dogs had hyperkalemia but none of those dogs had a combination
of hyponatremia and hyperkalemia. None of the 6 dogs with HA
had hyperkalemia or hyponatremia, but 2 dogs with signs of
TABLE 1 Hematology parameters of
151 dogs with chronic gastrointestinal
signs grouped by presence or absence of
hypoadrenocorticism (HA)
Variable
Dogs without HA Dogs with HA
P valueMedian Range Median Range
Hematocrit (l/L) 0.50 (n = 143) 0.34-0.66 0.46 (n = 6) 0.35-0.62 .20
MCV (f/L) 71 (n = 141) 57-88 68 (n = 6) 66-77 .53
Leukocytes (×109/L) 9.3 (n = 141) 4.6-63.5 13.0 (n = 6) 5.5-26.5 .18
Monocytes (×109/L) 0.41 (n = 138) 0.14-1.48 0.53 (n = 6) 0.10-1.80 .33
Lymphocytes (×109/L) 1.71 (n = 139) 0.28-25.40 2.57 (n = 6) 0.99-5.97 .12
Neutrophils (×109/L) 6.37 (n = 137) 2.46-44.27 6.77 (n = 6) 3.86-22.30 .73
Eosinophils (×109/L) 0.46 (n = 135) 0.03-1.69 0.40 (n = 6) 0.03-1.40 .86
Thrombocytes (×109/L) 252 (n = 139) 77-875 224 (n = 6) 115-421 .54
TABLE 2 Serum biochemistry parameters of 151 dogs with chronic gastrointestinal signs grouped by presence or absence of
hypoadrenocorticism (HA)
Variables
Dogs without HA Dogs with HA
P valueMedian Range Median Range
ALT (U/L) 48 (n = 145) 9-531 91 (n = 6) 52-581 .02
AP (U/L) 41 (n = 145) 11-590 46 (n = 6) 26-678 .52
Bilirubin (μmol/L) 3.42 (n = 144) 0.10-6.84 3.42 (n = 6) 2.10-5.13 .70
Cholesterol (mmol/L) 5.68 (n = 142) 1.12-14.14 2.49 (n = 6) 0.90-7.59 .05
Triglyceride (mmol/L) 0.58 (n = 104) 0.24-2.75 0.36 (n = 4) 0.17-0.73 .06
Total protein (g/L) 61 (n = 145) 25-86 62 (n = 6) 53-85 .66
Albumin (g/L) 32.50 (n = 145) 7.70-39.50 35.00 (n = 6) 21.00-42.10 .38
Urea (mmol/L) 3.16 (n = 145) 1.00-18.48 4.41 (n = 6) 1.33-24.00 .42
Creatinine (μmol/L) 79.56 (n = 144) 26.52-282.89 77.28 (n = 6) 44.20-97.24 .76
Glucose (mmol/L) 5.11 (n = 144) 2.61-9.10 4.44 (n = 6) 3.77-6.77 .16
Folic acid (ng/mL) 10.90 (n = 131) 2.16-43.70 13.70 (n = 6) 10.00-18.20 .11
Cobalamin (pg/mL) 352 (n = 138) 106-3362 295 (n = 6) 175-363 .12
TABLE 3 Electrolyte values of
151 dogs with signs of chronic
gastrointestinal disease grouped by
presence or absence of
hypoadrenocorticism (HA)
Variables
Dogs without HA Dogs with HA
P valueMedian Range Median Range
Sodium (mmol/L) 147 (n = 144) 114-152 146 (n = 6) 142-150 .65
Potassium (mmol/L) 4.3 (n = 144) 2.6-6.1 4.5 (n = 6) 3.9-4.9 .30
Calcium (mmol/L) 2.50 (n = 144) 1.26-3.10 2.55 (n = 6) 2.30-2.80 .90
Chloride (mmol/L) 113 (n = 143) 103-121 113 (n = 6) 95-121 .90
Phosphate (mmol/L) 1.1 (n = 143) 0.5-2.2 1.3 (n = 6) 1.0-2.1 .07
1402 HAUCK ET AL.
gastrointestinal bleeding had combined laboratory changes of anemia,
hypoalbuminemia, and increased urea.
Basal serum cortisol concentration was ≤3 μg/dL (≤83 nmol/L) in
80/151 dogs (53%), ≤2 μg/dL (≤55 nmol/L) in 42/151 dogs (28%),
and ≤1 μg/dL (≤28 nmol/L) in 9/151 dogs (6%) including all 6 dogs with
HA. The basal and stimulated serum cortisol concentrations of the ACTH
stimulation testing comparing dogs with HA (n = 6) and without HA
(n = 145) are shown in Figures 1 and 2. Serum cortisol concentrations
before and after the stimulation with ACTH for each individual group
(dogs with and without hypoadrenocorticism) are presented in Table 4,
as well as in Figure 3 and 4.
4 | DISCUSSION
This multicenter prospective study demonstrates a higher prevalence of
HA in dogs with chronic SGD presented to several referral centers in
Germany and in the Netherlands (4%) in comparison to the estimated
prevalence in the general canine population (between 0.06 and 0.28%).1,2
It is difficult to determine if the present study under- or over-
estimates the true prevalence of HA in dogs with chronic SGD. On the
one hand, underestimation is possible as not all dogs suffering from HA
might get referred or tested for HA. On the other hand, a referral popula-
tion might be biased toward rare diseases, as it is more likely that cases
that are difficult to diagnose or treat are referred, hence overestimating
true prevalence in the population. In this context, it is important to stress
that all dogs diagnosed with HA in the present study had GDH. The lack
of typical electrolyte abnormalities decreases the suspicion for the dis-
ease and testing is less likely to take place.
The signalment of the dogs diagnosed with HA in the present
study is somewhat different from previous studies, which is likely
F IGURE 1 Scatter plot showing basal serum cortisol
concentrations in 145 dogs without hypoadrenocorticism and 6 dogs
with hypoadrenocorticism. The horizontal bars represent the 25%
percentile, the median and the 75% percentile
F IGURE 2 Scatter plot showing stimulated serum cortisol
concentrations in 145 dogs without hypoadrenocorticism and 6 dogs
with hypoadrenocorticism. The horizontal bars represent the 25%
percentile, the median and the 75% percentile
F IGURE 3 Scatter plot showing serum cortisol concentrations in
6 dogs with hypoadrenocorticism before and after the stimulation
with ACTH
F IGURE 4 Scatter plot showing serum cortisol concentrations
before and after the stimulation with ACTH in 74 dogs without
hypoadrenocorticism and basal cortisol values < 3 μg/dL
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because of the fact that classical presentations with typical electrolyte
changes are missing in the present population.2,27,28
Absence of mineralocorticoid deficiency puts these dogs in a sta-
ble hemodynamic state, which can explain why they are diagnosed
later compared to dogs with typical features of HA (MGDH). How-
ever, also dogs with proven mineralocorticoid deficiency can poten-
tially maintain normal electrolyte concentrations for an extended
period of time, if conditions causing hypovolemia do not occur.29
Five of six dogs with HA had signs of GI blood loss. In 4/6 dogs
melena or hematochezia was noted by the owner and 1/6 dogs had
anemia and hypalbuminemia most likely because of GI loss. As gluco-
corticoids have an important influence on epithelial integrity and vas-
cular permeability and they can act as trophic factors for the GI
mucosa, it is possible that the lack of glucocorticoids predisposes indi-
viduals to mucosal erosions and ulcers and hence hemorrhage.30,31
Neither historical information nor clinicopathological data were
helpful to distinguish dogs with and without HA in the examined pop-
ulation. Moreover, no clinicopathological data were helpful to discrim-
inate HA from other causes of chronic SGD.
28% of all dogs in this study had a basal serum cortisol concen-
tration ≤2 μg/dL (≤55 nmoL/L). Dogs with chronic disease might be
expected to have higher cortisol concentrations. Our results however
show that chronic SGD are not generally associated with an increased
stimulation of the hypothalamus-adrenal axis. This finding is consistent
with other reports demonstrating that 33% of dogs with nonadrenal ill-
ness have a serum basal cortisol concentrations ≤2 μg/dL (≤55 nmoL/
L).32 On the other hand, a serum basal cortisol concentration >2 μg/dL
(>55 nmoL/L) is considered useful in excluding a diagnosis of HA.21,23 In
most dogs with HA serum basal cortisol concentrations are <1 μg/dL, but
few dogs can have a value between 1 and 2 μg/dL. Therefore, further
adrenal function testing (eg, ACTHST, cortisol:endogenous ACTH ratio) is
recommended in every dog with a value ≤2 μg/dL, which according to
our results might be necessary in about 1/3 of dogs with chronic SGD to
definitively diagnose or rule out HA.
The authors believe all 6 dogs with inappropriate response to
ACTH have true “atypical” HA. Laboratory error (both assay variation
or failure as well as a clerical error) cannot be fully excluded, but
ACTH stimulation tests were performed as per standard operating
procedure and with due diligence. By having stringent inclusion and
exclusion criteria, every effort was made to eliminate dogs from the
study that might have any residual glucocorticoid effects and hence
persistent suppression of the HPA from any previous treatments.
However, as currently no guidelines exist regarding the required time
span until ACTH testing can be performed after a dog has been
treated with different steroid formulations, a possible influence of
prior steroid administration cannot be fully excluded.
This study was not set up to differentiate primary HA from second-
ary HA, hence endogenous ACTH was not measured. Although second-
ary HA is rare,33 it needs to be considered in dogs with HA without
electrolyte abnormalities. Determination of endogenous ACTH would
also have been advantageous to rule out prior administration of gluco-
corticoids, which would likely result in an ACTH-stimulation mimicking
hypoadrenocorticism. However, as a thorough drug history was taken
for each dog it seems unlikely that the dogs identified to have no stim-
ulation of cortisol production after ACTH administration were
misdiagnosed.
Equally, aldosterone concentrations were not measured that
would be necessary to document presence or absence of mineralocor-
ticoid deficiency. Decreased aldosterone concentration could be pre-
sent even in the absence of electrolyte abnormalities in some dogs
with HA.29
In conclusion, the prevalence of HA among dogs with chronic
SGD seen in Germany and the Netherlands is significantly higher com-
pared to the reported prevalence in the general dog population.1,2
Because approximately 1 in 25 dogs with chronic SGD might have
HA, ruling out HA should be an important additional step in the stan-
dard approach of dogs with chronic SGD. Episodes of GI bleeding
should specifically raise the suspicion; however, no differentiation
between HA and other causes leading to chronic SGD is possible
based on history, physical examination, or routine blood work. Deter-
mination of basal serum cortisol concentration should be performed
as a standard screening test for HA, followed by further endocrine
testing if baseline cortisol concentration is ≤2 μg/dL.
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